CA2699702C - Cancer marker and therapeutic target - Google Patents
Cancer marker and therapeutic target Download PDFInfo
- Publication number
- CA2699702C CA2699702C CA2699702A CA2699702A CA2699702C CA 2699702 C CA2699702 C CA 2699702C CA 2699702 A CA2699702 A CA 2699702A CA 2699702 A CA2699702 A CA 2699702A CA 2699702 C CA2699702 C CA 2699702C
- Authority
- CA
- Canada
- Prior art keywords
- ccr4
- tumour
- cells
- cancer
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001225 therapeutic effect Effects 0.000 title description 7
- 239000012830 cancer therapeutic Substances 0.000 title description 2
- 239000000439 tumor marker Substances 0.000 title description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims abstract description 297
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 285
- 201000011510 cancer Diseases 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 106
- 230000000694 effects Effects 0.000 claims abstract description 58
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 41
- 239000003446 ligand Substances 0.000 claims abstract description 38
- 238000012216 screening Methods 0.000 claims abstract description 22
- 230000004071 biological effect Effects 0.000 claims abstract description 15
- 239000013610 patient sample Substances 0.000 claims abstract description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims abstract 36
- 210000004027 cell Anatomy 0.000 claims description 279
- 230000014509 gene expression Effects 0.000 claims description 124
- 239000000523 sample Substances 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 50
- 210000004881 tumor cell Anatomy 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000002489 hematologic effect Effects 0.000 claims description 42
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 238000011394 anticancer treatment Methods 0.000 claims description 20
- 102000004498 CCR4 Receptors Human genes 0.000 claims description 16
- 108010017317 CCR4 Receptors Proteins 0.000 claims description 16
- 210000004556 brain Anatomy 0.000 claims description 16
- 210000000481 breast Anatomy 0.000 claims description 15
- 230000005012 migration Effects 0.000 claims description 15
- 238000013508 migration Methods 0.000 claims description 15
- 210000003734 kidney Anatomy 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- 230000011664 signaling Effects 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 210000001672 ovary Anatomy 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 10
- 210000002307 prostate Anatomy 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229940126669 CCR4 antagonist Drugs 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- WYVBISCFCHREDA-UHFFFAOYSA-N n-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCC(CC2)N2CCCCC2)=NC=1NC1CCCCCC1 WYVBISCFCHREDA-UHFFFAOYSA-N 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000013074 reference sample Substances 0.000 claims description 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 238000013517 stratification Methods 0.000 abstract description 6
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 258
- 230000003211 malignant effect Effects 0.000 description 65
- 210000001519 tissue Anatomy 0.000 description 56
- 238000001574 biopsy Methods 0.000 description 41
- 210000002919 epithelial cell Anatomy 0.000 description 40
- 206010041823 squamous cell carcinoma Diseases 0.000 description 39
- 206010008342 Cervix carcinoma Diseases 0.000 description 34
- 201000010881 cervical cancer Diseases 0.000 description 34
- 108020004999 messenger RNA Proteins 0.000 description 31
- 210000003679 cervix uteri Anatomy 0.000 description 27
- 102000009410 Chemokine receptor Human genes 0.000 description 26
- 108050000299 Chemokine receptor Proteins 0.000 description 26
- 230000001613 neoplastic effect Effects 0.000 description 24
- 102000019034 Chemokines Human genes 0.000 description 23
- 108010012236 Chemokines Proteins 0.000 description 23
- 238000003364 immunohistochemistry Methods 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 208000009956 adenocarcinoma Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 18
- 210000002536 stromal cell Anatomy 0.000 description 17
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 16
- 102100025136 Macrosialin Human genes 0.000 description 16
- 210000003289 regulatory T cell Anatomy 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 13
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 206010058314 Dysplasia Diseases 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 9
- 238000009595 pap smear Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 101150029707 ERBB2 gene Proteins 0.000 description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 230000012292 cell migration Effects 0.000 description 7
- 230000035605 chemotaxis Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- -1 phospho Chemical class 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108010083701 Chemokine CCL22 Proteins 0.000 description 5
- 102000006433 Chemokine CCL22 Human genes 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000004709 cell invasion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002390 hyperplastic effect Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000037451 immune surveillance Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000003739 neck Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 3
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 206010038111 Recurrent cancer Diseases 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000003500 gene array Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220002645 rs104894309 Human genes 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- JKPSVOHVUGMYGH-UHFFFAOYSA-M sodium;(4,6-dimethoxypyrimidin-2-yl)-[[3-methoxycarbonyl-6-(trifluoromethyl)pyridin-2-yl]sulfonylcarbamoyl]azanide Chemical compound [Na+].COC(=O)C1=CC=C(C(F)(F)F)N=C1S(=O)(=O)NC(=O)[N-]C1=NC(OC)=CC(OC)=N1 JKPSVOHVUGMYGH-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 108010039171 CC cytokine receptor-4 Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 101150081315 CCR4 gene Proteins 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 102000003826 Chemokine CCL17 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000922140 Drosophila melanogaster Peripheral plasma membrane protein CASK Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000029847 chemokine (C-C motif) ligand 22 production Effects 0.000 description 1
- 108010089833 chemokine receptor D6 Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035926 haptotaxis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000001001 laser micro-dissection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015047 pilsener Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0718167A GB0718167D0 (en) | 2007-09-18 | 2007-09-18 | Cancer marker and therapeutic target |
| GB0718167.0 | 2007-09-18 | ||
| PCT/GB2008/003160 WO2009037454A2 (en) | 2007-09-18 | 2008-09-18 | Cancer marker and therapeutic target |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2699702A1 CA2699702A1 (en) | 2009-03-26 |
| CA2699702C true CA2699702C (en) | 2018-03-06 |
Family
ID=38670078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2699702A Expired - Fee Related CA2699702C (en) | 2007-09-18 | 2008-09-18 | Cancer marker and therapeutic target |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9134293B2 (enExample) |
| EP (3) | EP2533047B1 (enExample) |
| JP (2) | JP5774309B2 (enExample) |
| AU (1) | AU2008300413B2 (enExample) |
| CA (1) | CA2699702C (enExample) |
| DK (3) | DK2533047T3 (enExample) |
| ES (3) | ES2588507T3 (enExample) |
| GB (1) | GB0718167D0 (enExample) |
| PL (3) | PL2533047T3 (enExample) |
| RU (2) | RU2529797C2 (enExample) |
| WO (1) | WO2009037454A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623815Y2 (ja) | 1988-10-06 | 1994-06-22 | 株式会社大金製作所 | エア回転継手のシール装置 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| US11029313B2 (en) | 2008-09-26 | 2021-06-08 | The General Hospital Corporation | Method of treating cervical neoplasia in patients infected with human papilloma virus |
| US9229004B2 (en) | 2008-09-26 | 2016-01-05 | The General Hospital Corporation | Methods for detecting and treating cancer |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| WO2011157678A1 (en) * | 2010-06-14 | 2011-12-22 | Qiagen Gmbh | Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| JP6259764B2 (ja) * | 2011-10-24 | 2018-01-10 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | 炭酸脱水酵素関連マーカーおよびその使用 |
| JP6141864B2 (ja) | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換アニリン |
| GB2512857A (en) * | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
| EP3466445A1 (en) * | 2013-11-06 | 2019-04-10 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
| US10155818B2 (en) | 2014-05-28 | 2018-12-18 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| WO2016050904A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject |
| MX2017013390A (es) * | 2015-04-17 | 2018-06-13 | Morphotek Inc | Método para el tratamiento de cáncer pulmonar. |
| WO2017017283A1 (en) | 2015-07-30 | 2017-02-02 | Qiagen Gmbh | Method of preparing a frozen biological sample |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3626269A4 (en) * | 2017-05-19 | 2021-03-03 | Shingo Maeda | Method for inhibiting regulatory t cell infiltration using ccr4 inhibition and method for treating canine neoplastic disease |
| CA3109498A1 (en) | 2018-08-29 | 2020-03-05 | Chemocentryx, Inc. | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| EP0689606A1 (en) * | 1993-03-19 | 1996-01-03 | The Johns Hopkins University | ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| KR100890873B1 (ko) | 2000-03-03 | 2009-03-31 | 교와 핫꼬 기린 가부시키가이샤 | 유전자 재조합 항체 및 이의 항체 단편 |
| US20020132836A1 (en) | 2000-10-11 | 2002-09-19 | Chemocentryx Inc. | Compounds and methods for modulating CCR4 function |
| CA2425259A1 (en) | 2000-10-11 | 2002-04-18 | Tularik, Inc. | Modulation of ccr4 function |
| HUP0301433A3 (en) | 2000-10-18 | 2010-01-28 | Schering Ag | Use of antiprogestins for producung pharmaceutical compositions for induction of apoptosis in a cell |
| US20020182624A1 (en) * | 2001-02-28 | 2002-12-05 | Eos Biotechnology, Inc. | Chemokine receptors and disease |
| US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
| US20050101530A1 (en) | 2001-08-10 | 2005-05-12 | Topigen Pharmaceutique, Inc. | Cellular virus receptors and methods of use |
| ATE490277T1 (de) | 2001-08-31 | 2010-12-15 | Kyowa Hakko Kirin Co Ltd | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| EP2058408A3 (en) * | 2003-02-14 | 2009-09-09 | Sagres Discovery, Inc. | Therapeutic GPCR targets in cancer |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| SE0301650D0 (sv) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| EP1688436A4 (en) * | 2003-10-08 | 2009-12-02 | Kyowa Hakko Kirin Co Ltd | ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY |
| CA2548454C (en) | 2003-12-04 | 2013-12-31 | Kyowa Hakko Kogyo Co., Ltd. | Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP2007217282A (ja) | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
| WO2005106471A2 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) |
| JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| RU2296328C1 (ru) * | 2005-09-21 | 2007-03-27 | Общество с ограниченной ответственностью "ГЕН" | Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| CN103275984A (zh) | 2006-02-14 | 2013-09-04 | 诺松制药股份公司 | 结合mcp-1的核酸 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
-
2007
- 2007-09-18 GB GB0718167A patent/GB0718167D0/en not_active Ceased
-
2008
- 2008-09-18 CA CA2699702A patent/CA2699702C/en not_active Expired - Fee Related
- 2008-09-18 EP EP12182790.1A patent/EP2533047B1/en not_active Not-in-force
- 2008-09-18 WO PCT/GB2008/003160 patent/WO2009037454A2/en not_active Ceased
- 2008-09-18 AU AU2008300413A patent/AU2008300413B2/en not_active Ceased
- 2008-09-18 ES ES12182790.1T patent/ES2588507T3/es active Active
- 2008-09-18 DK DK12182790.1T patent/DK2533047T3/en active
- 2008-09-18 PL PL12182790.1T patent/PL2533047T3/pl unknown
- 2008-09-18 RU RU2010123921/15A patent/RU2529797C2/ru not_active IP Right Cessation
- 2008-09-18 ES ES08806315.1T patent/ES2443541T3/es active Active
- 2008-09-18 PL PL12183760T patent/PL2535716T3/pl unknown
- 2008-09-18 DK DK08806315.1T patent/DK2176664T3/da active
- 2008-09-18 ES ES12183760.3T patent/ES2612690T3/es active Active
- 2008-09-18 PL PL08806315T patent/PL2176664T3/pl unknown
- 2008-09-18 EP EP08806315.1A patent/EP2176664B1/en not_active Not-in-force
- 2008-09-18 EP EP12183760.3A patent/EP2535716B1/en not_active Not-in-force
- 2008-09-18 JP JP2010525420A patent/JP5774309B2/ja not_active Expired - Fee Related
- 2008-09-18 DK DK12183760.3T patent/DK2535716T3/en active
- 2008-09-18 US US12/679,002 patent/US9134293B2/en not_active Expired - Fee Related
-
2014
- 2014-07-14 RU RU2014128513A patent/RU2014128513A/ru not_active Application Discontinuation
-
2015
- 2015-06-30 JP JP2015131752A patent/JP6234967B2/ja not_active Expired - Fee Related
- 2015-08-11 US US14/823,755 patent/US10261099B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2176664A2 (en) | 2010-04-21 |
| AU2008300413B2 (en) | 2014-09-11 |
| RU2010123921A (ru) | 2011-12-20 |
| DK2535716T3 (en) | 2017-02-13 |
| EP2535716A3 (en) | 2013-03-13 |
| DK2533047T3 (en) | 2016-08-22 |
| US20100278844A1 (en) | 2010-11-04 |
| RU2529797C2 (ru) | 2014-09-27 |
| EP2176664B1 (en) | 2013-11-06 |
| US9134293B2 (en) | 2015-09-15 |
| EP2535716B1 (en) | 2016-11-02 |
| EP2533047A1 (en) | 2012-12-12 |
| JP2015212703A (ja) | 2015-11-26 |
| ES2588507T3 (es) | 2016-11-03 |
| JP2010539508A (ja) | 2010-12-16 |
| AU2008300413A1 (en) | 2009-03-26 |
| US10261099B2 (en) | 2019-04-16 |
| RU2014128513A (ru) | 2016-02-10 |
| JP6234967B2 (ja) | 2017-11-22 |
| EP2533047B1 (en) | 2016-05-11 |
| WO2009037454A3 (en) | 2009-05-07 |
| US20160223572A1 (en) | 2016-08-04 |
| JP5774309B2 (ja) | 2015-09-09 |
| PL2533047T3 (pl) | 2016-11-30 |
| CA2699702A1 (en) | 2009-03-26 |
| PL2176664T3 (pl) | 2014-04-30 |
| ES2443541T3 (es) | 2014-02-19 |
| DK2176664T3 (da) | 2014-01-20 |
| GB0718167D0 (en) | 2007-10-31 |
| WO2009037454A2 (en) | 2009-03-26 |
| PL2535716T3 (pl) | 2017-06-30 |
| ES2612690T3 (es) | 2017-05-18 |
| EP2535716A2 (en) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2699702C (en) | Cancer marker and therapeutic target | |
| Scala et al. | Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma | |
| Ottaiano et al. | Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells | |
| Agaimy et al. | HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology | |
| Palou et al. | Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin | |
| CN102667484A (zh) | 识别黑素瘤肿瘤细胞的生物标记 | |
| JP2013520958A (ja) | 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法 | |
| JP2016522879A (ja) | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー | |
| Wang et al. | Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer | |
| US20150004253A1 (en) | Method for the prognosis of survival time of a patient suffering from a solid cancer | |
| JP2020040959A (ja) | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 | |
| Hermida-Prado et al. | Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer | |
| Frolova et al. | A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers | |
| JP2021523351A (ja) | レンバチニブ及びｐｄ−１アンタゴニストを含む組み合わせ療法のためのバイオマーカー | |
| Kim et al. | Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast with Clinicopathologic Features and T-Cell Infiltration | |
| AU2013203369B2 (en) | Cancer marker and therapeutic target | |
| CN116137862A (zh) | 三级淋巴结构在预后疾病进展和治疗癌症中的应用 | |
| JP5145549B2 (ja) | 腫瘍マーカー | |
| Yokouchi et al. | Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer | |
| JP2019518970A (ja) | 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット | |
| Pagano | The potential role of CXCR4 and SDF-1 as indicators of tumor aggressiviness in patients with conventional papillary thyroid carcinoma | |
| Devictor et al. | cytochemical Assays of P-glycoprotein in Breast | |
| Musrap | Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer | |
| DeRycke | S100A1 and nectin 4 biomarkers in ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130912 |
|
| MKLA | Lapsed |
Effective date: 20210920 |